#	Pagina
attuale pagina	/open-h2020/projects/208141/index.html

Opendata, web and dolomites

GAIT

From symptom relief to disease modifying allergy treatment with Glycan-Allergen Immunotherapy

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

GAIT project word cloud

Explore the words cloud of the GAIT project. It provides you a very rough idea of what is the project "GAIT" about.

plans medical replace dc4u protection followed tolerance modifying immune iia worldwide allergens immunotherapy dominated protein generation initialize pollen mechanisms allergen diseases pharmaceutical attempts elaborate ipr placebo endogenous plan patient therapy pace shown recognition strategy healthcare refine investors ait efficacy chronic disease allergy sia responsible clinical suited curative negotiations prevalence medicine incorporated risks sme treat profitability proprietary cured license instead relieving inducing decongestants individuals safe doses alleviating vivo 20 licensing human substances alarming dose severe extract trials therapeutics company underlying treatment grass business course healthy harm antihistamines self develops corticosteroids characterised market glycans annual global life elaborated gp symptom

Project "GAIT" data sheet

The following table provides information about the project.

Coordinator	DC4U Organization address address: DE CORRIDOR 21E city: BREUKELEN postcode: 3621 ZA website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.dc4u-technologies.nl
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2017
Duration (year-month-day)	from 2017-03-01 to 2017-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	DC4U DC4U Organization address address: DE CORRIDOR 21E city: BREUKELEN postcode: 3621 ZA website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (BREUKELEN)	coordinator	50˙000.00

Map

Project objective

The annual increase in prevalence of allergy related diseases develops at an alarming pace worldwide. Responsible disease mechanisms are characterised by unwanted immune responses to substances which do not harm healthy individuals. The allergy therapeutics market is now dominated by symptom alleviating antihistamines, decongestants and corticosteroids. The main patient need is to get cured with a disease modifying medicine instead of the chronic use of symptom relieving products. Allergen-specific Immunotherapy (AIT) attempts to treat the underlying cause by inducing allergen-specific immune tolerance. However, currently used AIT with high doses of extract is not effective enough (only 20% better than placebo), risks severe side effects and requires 5 years of treatment.

DC4U is developing a new generation of disease modifying allergy treatment with the potential to replace symptom relieving products and current AIT. We apply a new and unique technology to present allergens to the immune system as being SELF and SAFE, using glycans as endogenous human protein recognition elements. Our lead product, “sia-GP”, is a grass pollen allergy treatment for life long protection, achieved in a short treatment course. DC4U has shown highly promising in-vivo dose-response efficacy results and will further develop this proprietary product up to and including Phase IIa clinical trials. This will be followed by out-licensing to a pharmaceutical company. Effective curative tolerance inducing therapy will contribute to global medical needs and reduction of healthcare costs.

In this SME-1 we will elaborate and refine our clinical plans, IPR strategy, market analysis and profitability analysis. Furthermore, we will initialize discussions and negotiations with several possible investors and licensing partners. All will be incorporated in an elaborated European business plan with best suited to out-license sia-GP after Phase IIa clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAIT" are provided by the European Opendata Portal: CORDIS opendata.